Skip to main content

Heron Therapeutics Value Stock - Dividend - Research Selection

Heron therapeutics

ISIN: US4277461020 , WKN: A1XB6K

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company\'s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

2024-12-23
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States. The growing biotech co

Heron Therapeutics : Announces Corporate Headquarters Relocation to Cary, North Carolina Form 8 K

2024-12-23
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina SAN DIEGO, December 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage...

Exploring Three High Growth Tech Stocks In The United States

2024-12-11
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high growth tech stocks that align with these positive trends can be key for investors seeking opportunities in an evolving market landscape.

Relief For Heron Therapeutics After The Court Win On Cinvanti

2024-12-04
Heron Therapeutics’ court win strengthens its position for 2025. Find out why HRTX stock shows potential for a recovery despite missed Q3 estimates.

U.S. District Court Upholds Validity of CINVANTI® Patents

2024-12-03
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic

Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues

2024-11-30
Heron has characteristics that are associated with high risk investments.

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

2024-11-20
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.

Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...

2024-11-13
Heron Therapeutics Inc (HRTX) reports a significant increase in gross profit margin and outlines strategic plans to overcome revenue hurdles in a competitive market.

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

2024-11-12
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

2024-11-12
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?